Tycel Phillips News Today

Tycel Phillips, MD, MPH, discusses updated efficacy and safety data with glofitamab for the treatment of relapsed/refractory mantle cell lymphoma.

Tycel Phillips, MD, discusses the rationale for launching the phase 3 GLOBRYTE trial evaluating glofitamab monotherapy in patients with relapsed/refractory mantle cell lymphoma, highlighting ongoing enrollment efforts.

Tycel Phillips, MD, discusses current and emerging therapeutic treatment strategies for patients with mantle cell lymphoma.

Tycel Phillips, MD, MPH, discusses the use of bispecific antibodies and CAR T-cell therapy across hematologic malignancies, including in patients with mantle cell lymphoma and follicular lymphoma.

Tycel Phillips, MD, MPH, discusses the ongoing phase 3 ECHO trial of acalabrutinib plus bendamustine and rituximab in the front line for patients with mantle cell lymphoma.

Tycel Phillips, MD, discusses the rationale and design of a phase 1b trial investigating acalabrutinib plus bendamustine and rituximab in patients with mantle cell lymphoma, highlights key efficacy and safety findings in the treatment-naïve and relapsed/refractory patient cohorts, and postulated next steps on the horizon for investigating BTK inhibitors in combination with chemotherapy in this patient population.

Tycel Phillips, MD, MPH, discusses the updated safety profile and clinical activity seen with the addition of acalabrutinib to bendamustine and rituximab in patients with mantle cell lymphoma.

Tycel Phillips, MD, hematologist-oncologist at City of Hope in Duarte, California, discusses the need for novel treatments for patients with diffuse large B-cell lymphoma (DLBCL).

Dr Phillips discusses the FDA approval of epcoritamab in patients with relapsed/refractory DLBCL key efficacy and safety findings from the EPCORE NHL-1 trial, and the potential future of bispecific antibodies in this setting.

The addition of acalabrutinib to bendamustine and rituximab demonstrated potent and durable responses despite a high incidence of grade 3/4 adverse effects in patients with previously untreated and relapsed/refractory mantle cell lymphoma.